TSGH Société par actions simplifiée

About TSGH Société par actions simplifiée

TSGH Société par actions simplifiée is the reference financial holding company and majority shareholder of Transgene S.A. since 1994, within the Institut Mérieux group. The person most closely associated with this vehicle from a corporate-governance standpoint is Philippe Archinard, whom Transgene identifies as Chief Executive Officer of TSGH. TSGH is ultimately owned by the Mérieux family and the Rodolphe and Christophe Mérieux Foundation, giving the structure a stable, long-term ownership profile closely aligned with healthcare innovation. At Transgene, TSGH plays a strategic role as majority shareholder and board member, having served on the Board of Directors since 2002. This long-standing presence supports capital stability, continuity in oversight, and consistent backing for the company’s development strategy. Transgene also states that Sandrine Flory has been TSGH’s permanent representative on the Board since January 2021, underlining the continuity of the relationship between the holding company and the listed biotech. From a governance and expertise perspective, TSGH is embedded in a framework of strategic supervision, financing, and board-level stewardship for a listed biotechnology company focused on cancer immunotherapies. Transgene’s disclosures also reference capital-related transactions involving TSGH, including a partial conversion of a shareholder current account advance into shares, illustrating the holding’s role in financing support and capital structure management. TSGH therefore stands out as a long-term reference shareholder with a governance-oriented profile, bringing financial discipline, strategic continuity, and an industrial-healthcare anchor to Transgene. In practical terms, its influence is reflected in board stability, support for the company’s capital structure, and sustained backing for the execution of Transgene’s innovative immunotherapy portfolio.